Pharmicell posted record results last year, with revenue of 114 billion won and operating profit of 34.3 billion won, the highest since its founding. Revenue rose 75% from a year earlier, and operating profit jumped 637%. Net profit came to 40.3 billion won, up 536%.
Fourth-quarter revenue rose 61% from a year earlier to 34.6 billion won, marking a quarterly record high. Operating profit for the same period also hit a record, climbing 207% to 9.6 billion won despite seasonal one-off expense recognition.
The biochemicals institutional sector led the earnings improvement. The institutional sector, which produces low-dielectric electronic materials and active pharmaceutical ingredients (API), generated 111.5 billion won in revenue, accounting for 97% of the total.
In particular, sales of low-dielectric electronic materials used in advanced equipment such as artificial intelligence (AI) accelerators, 5G network equipment, and base station antennas surged. Annual revenue reached 64.7 billion won, up 118% from 29.7 billion won a year earlier, accounting for 56% of total sales. This is comparable to Pharmicell's total revenue of 64.8 billion won in the previous year.
The active pharmaceutical ingredients business also entered a growth trajectory. Related revenue last year was 20.4 billion won, up 84% from a year earlier.
A Pharmicell official said, "We are earning customers' trust in both fields of low-dielectric electronic materials and active pharmaceutical ingredients based on differentiated technological prowess and quality competitiveness," and added, "We will boost productivity by improving processes on existing production lines and significantly expand production capacity with the completion of Plant 3 in the second half of this year to reinforce the foundation for sustained growth."